Title Analysis of RNA in bodily fluids for prostate cancer diagnosis and outcome prediction
Translation of Title Organizmo skysčių RNR tyrimai prostatos vėžio diagnostikai ir ligos eigos prognozavimui.
Authors Stuopelytė, Kristina
Full Text Download
Pages 60
Keywords [eng] prostate cancer ; miRNA ; androgen receptor ; liquid biopsy
Abstract [eng] Although local PCa treatment is quite effective and aggressive disease develops for a minority of patients, such PCa cases are associated with worse prognosis and shorter survival; also there is a lack of reliable biomarkers for the evaluation of response to treatment. Blood- and urine-circulating RNA can be used as lowly-invasive biomarkers for diagnostic and prognostic purposes in PCa. We found that miR-148a, -365, -375, and -429 are PCa-specific and have significant associations with clinical-pathological parameters of PCa. Also we demonstrated that the combination of urinary miR-148a and miR-375 is a sensitive molecular tool for noninvasive diagnosis of PCa, while the combination of miR-19b and miR-19a/b specifically predicts biochemical recurrence. Castration resistant prostate cancer (CRPC) remains incurable. Due to the heterogeneous nature of CRPC, approximately 30% of patients are already resistant to these new drugs. In patients treated with abiraterone acetate (AA), urinary miR-148 predicts progression-free survival, while the combination of miR-148a and miR-375 – overall survival. One of the resistance mechanisms could be AR splicing variants (AR-Vs) which lack a ligand binding domain and are constitutively active. We demonstrated that higher level of AR-FL and -V1 transcripts in AA-treated CRPC patients’ blood predicts progression-free survival and overall survival.
Dissertation Institution Vilniaus universitetas.
Type Summaries of doctoral thesis
Language English
Publication date 2020